%0 Generic
%A Montesinos, P
%A Ballesteros, J
%A Martinez Cuadron, D
%A Martinez Lopez, J
%A Serrano, J
%A Perez de Oteyza, J
%A Fernandez, P
%A Rodriguez Macias, G
%A Vidriales, B
%A Herrera, P
%A Tormo, M
%A Bergua, J
%A Garcia, R
%A Vives, S
%A Fernandez, MA
%A Lavilla, E
%A Jimenez, S
%A Perez Simon, JA
%A Simiele, A
%A Gonzalez, A
%A Gonzalez, B
%A Burgaleta, C
%A Lopez, JA
%A Bethancourt, C
%A Bautista, G
%A Alonso, A
%A Colorado, M
%A Sierra, J
%A Navas, B
%A Hernandez Rivas, JA
%A Vera, JA
%A Amador, L
%A Cordoba, R
%A de la Fuente, A
%A Ramos, F
%A Cervero, CJ
%A Rayon, C
%A Salamero, O
%A Marti, E
%A Loez, A
%A Olave, T
%A Gaspar, M
%A Gorrochategui, J
%A Rojas, JL
%A Gomez, C
%A Hernandez, P
%A Robles, A
%A Ortega, I
%A Villoria, J
%A Moscardo, F
%A Troconiz, I
%A Sanz, MA
%T An ex vivo native environment precision medicine test shows high clinical correlation with responses to first line acute myeloid leukemia treatment
%D 2016
%@ 0390-6078
%U http://hdl.handle.net/10668/2442
%X This novel test is able to predict the clinical response to Ida+Ara-C induction with overall correlation and predictive values of 80%, higher than ever achieved. Considering this result and current clinical responserate of 66.7% (70% in this study), clear clinical benefits can be achieved withthe use of the test. Adding the cytogenetic risk profile further increase the correlationto 90%. Thus this novel test may be valuable information to guide 1st line patient therapy
%K Adulto
%K Médula ósea
%K Citarabina
%K Ambiente
%K Humanos
%K Idarrubicina
%K Quimioterapia de inducción
%K Mantenimiento
%~